Hanumunthadu, Daren
Saleh, Azahir
Florea, Daniela
Balaskas, Konstantinos
Keane, Pearse A
Aslam, Tariq
Patel, Praveen J.
Funding for this research was provided by:
Bayer
Article History
Received: 11 September 2022
Accepted: 19 December 2022
First Online: 14 February 2023
Declarations
:
: This study had ethics approval from Moorfields Eye Hospital Research Ethics Committee. All subjects gave informed consent prior to inclusion.
: Not applicable
: The authors declare no relevant funding resources or competing interests. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health.Dr Keane has acted as a consultant for DeepMind, Roche, Novartis, and Apellis and is an equity owner in Big Picture Medical. He has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer. Dr Keane is supported by a Moorfields Eye Charity Career Development Award (R190028A) and a UK Research & Innovation Future Leaders Fellowship (MR/T019050/1).Dr Balaskas has received speaker fees from Novartis, Bayer, Alimera, Allergan and Heidelberg, consulting fees from Novartis and Roche and research support from Apellis, Roche, Novartis and Bayer.Dr Patel has received speaker fees from Novartis, Bayer, Topcon and Heidelberg, consulting fees from Novartis, Bayer, Oxford Bioelectronics and Roche and research support from Bayer.Professor Aslam has received speaker and consultancy fees from Novarits, Bayer, Roche, Topcon, Heidelberg, Alimera, Allergan, Canon, Thea.